NCT07838740RecruitingPhase 1
A Phase 1 Study of VK2735 in Obese Adults Without Comorbidities
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VK2735 Administration in Adults Who Are Obese (BMI ≥ 30 kg/m2) Without Comorbidities
Source: ClinicalTrials.gov · Last updated 24 Sept 2026
Brief summary (registry, in English)
The goal of this Phase 1, randomized, double-blind, placebo-controlled study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VK2735 in adults who are obese (BMI ≥ 30 kg/m2) without comorbidities.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 270 (estimated)
- First submitted
- 9 Sept 2026
- Start date
- 18 Nov 2025
- Primary completion date
- May 2027
- Lead sponsor
- Viking Therapeutics, Inc.
- Diseases
- Obesity
- NCT number
- NCT07838740
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 270
- From 18 Nov 2025 to the primary completion date, May 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Any surgical or medical condition (active or chronic) that may interfere with IP distribution, metabolism, excretion or drug absorption.
- Any condition that might compromise safety or other endpoints in the study as judged by the Sponsor (or designee) or Investigator.
- History or presence of clinically significant acute or unstable cerebrovascular (stroke), hepatic, renal, gastrointestinal, pulmonary, immunological, endocrine, hematological, oncological, or central nervous disorder that in the opinion of the Investigator would pose a significant risk for the participant.
- Current or past diagnosis of diabetes mellitus (including type 1 and type 2, except gestational diabetes).
- Have a personal or family history of medullary thyroid carcinoma (MTC) or have multiple endocrine neoplasia syndrome type 2 (MEN-2).
Lab values
- Participants with any level of disease or organ system dysfunction as identified during physical examination, medical history, or laboratory testing, as assessed by the Investigator.
- Alanine aminotransferase (ALT) level or aspartate transaminase (AST) level \> 3.0 times the ULN for the reference range.
- Impaired renal function with estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73 m2 as measured at Screening.
Who the study is looking for
- Must be capable of giving a signed informed consent form (ICF).
- Must be medically healthy, with no significant medical history, have no clinically significant abnormalities on physical examination at Screening and/or before administration of the initial dose of IP in the opinion of the study Investigator.
- BMI ≥ 30 kg/m2.
- Willing to comply with contraceptive requirements.
Age in the registry: 18 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Lake Forest | United States | Recruiting |
| - Coordinator of this site? Confirm its status | Miami | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.